Introduction
Recent advances in endovascular technology have generated a variety of alternative procedures and instruments in treating peripheral arterial occlusive disease. Mechanical atherectomy has been developed as an alternative to conventional percutaneous transluminal angioplasty (PTA) because of its limitations. Atherectomy devices can selectively remove atheroma by cutting or pulverising it in atherosclerotic diseased arteries percutaneously with angiographic guidance or openly through a small arteriotomy distant from the diseased site under fluoroscopic or angioscopic control. Theoreticall3~ atherectomy offers three advantages over PTA: (1) greater immediate success rate with lower rates of intimal dissection and acute occlusion due to the controlled removal of atheroma from the lumen; (2) wider application to complex lesions not readily amenable to PTA; and (3) reduction of restenosis rate due to the debulking of atheromatous mass.
There are currently two types of atherectomy devices: extirpative and ablative. Extirpative atherectomy is characterised by shaving, cutting, or directly removing atheroma and collecting the excised material from the vessel lumen and wall. Ablative atherectom~ on the other hang uses a high-speed rotational device to pulverise atheroma into fragments small enough to be aspirated or removed through the reticuloendothelial system. The initial technical success and immediate clinical success rates of TEC atherectomy seem promising, but late follow-up has been either lacking or relatively short. Wholey and Jarmolowski 5 reported an impressive 92% technical success rate and a 90% dinical success rate. However, only 16 (17%) patients had undergone angiography at 6 months, 12 of whom revealed patent atherectomised lesions. Myers et al. 6 obtained an initial technical success of 86% and a clinical success of 74% in treating stenotic and occlusive lesions. Primary patency rates at 6 months were 80% for lesions < 5 cm and 64% for lesions > 5 cm. No long term patency results are available.
The initial technical success rates of the Trac-Wright catheter have ranged widely from 58% to 100% and clinical success rates from 33% to 80%. 7-1° However, follow-up has shown suboptimal patencies ranging from 25% to 68% at 6 months and 25% to 45% at 12 
Complications
Major complications of peripheral atherectomy devices include dissection, distal embolisation, haematoma, perforation, and thrombosis. With the Simpson device, Graor and Whitlow 2 reported seven cases of haematoma that required major intervention, including one patient who also developed a pseudoaneurysm. The TEC device, on the other hand, have caused various complications; Myers et al. 6 reported two deaths (1%) in patients with critical ischaemia, fracture of catheters requiring removal and replacement in two (1%), thromboembolism in two (1%), and bleeding at the puncture site in three (2%) within 30 days. In contradistinction to previous studies, ~4 the dissections and perforations encountered by some of the investigators 3, 8, 12, 13 suggest that the arterial wall did not always remain intact. Desbrosses et al. reported that perforation induced by the rotating cam of the Trac-Wright catheter occurred mostly in heavily calcified lesions due to the catheter's tendency to follow the path of least resistance, which is often away from hard calcified plaque, s Distal embolisations caused by atherectomy devices have been documented by some investigators. 5'9'~'13 Contrary to ~4 previous canine studies, the CRAG 12 and Henry et al. 13 demonstrated that some of the atherectomised particles generated by the Auth Rotablator can cause embolic complications. Furthermore, the CRAG 12 and Henry et al. ~3 reported nine (11%) and 12 (8%) early thromboses, respectively.
Limitations
Similar to PTA, restenosis and reocclusion are the primary constraints of atherectomy devices. At 6
Discussion
Each atherectomy device has been designed to address restenosis, reocclusion, and other problems that frequently plague the results of PTA. Each one has utilised remarkable technology to produce the aesthetic result of a smooth lumen without flaps, dissections, perforations, or other abnormalities and consequently reduce the likelihood of thromboembolisation, restenosis, and reocclusion. The Simpson AtheroCath has a retrieval chamber to collect the excised plaque; the TEC utilises a suction to aspirate the debris; the Trac-Wright catheter has a high speed rotating cam to micropulverise atheroma without damaging the arterial wall; the Auth Rotablator uses a high speed rotating burr to micropulverise hard calcified atheroma; and the OmniCath uses an anchoring deflector wire pad to prevent vessel wall injury and neointimal proliferation.
A review of the clinical investigations utilising atherectomy devices clearly establishes the feasibility of peripheral atherectomy in the treatment of arterial occlusive disease. However, inspite of the impressive and appealing technology of these devises, the efficacy of atherectomy remains questionable. Furthermore, none of the devices fulfill the aforementioned expectations without complications. Peripheral atherectomy currently has limited applications in the treatment of arterial occlusive disease. The problem of restenosis, reocclusion, and other complications must be solved before atherectomy devices can be used generally as an alternative to standard vascular reconstruction procedures or PTA. These problems can be solved only by addressing technological, mechanical, and biological factors in a rigorously scientific manner.
